Servier moved into muscular dystrophy by acquiring Edgewise Therapeutics’ muscular dystrophy business in a deal worth $1.55 billion upfront, with potential total value up to $2.65 billion including milestones. The transaction includes sevasemten (EDG-5506), a fast skeletal myosin inhibitor studied in Becker muscular dystrophy and in a phase 2 program in Duchenne muscular dystrophy. Servier said the acquisition fits its revenue growth strategy across oncology and neurology by adding a late-stage pipeline asset in a rare neuromuscular market with limited options. The deal also signals how specialty pharma continues to buy clinical-development risk in exchange for near-term pivotal-readiness timelines.